Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus

Antiviral Research

Volumn 75, Issue 1, 2007, Pages 36-42

  Rigopoulou, Eirini I ^a   Abbott, William G H ^a   Williams, Roger ^a   Naoumov, Nikolai V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Chronic hepatitis C; IFN ; IL 10; Ribavirin

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 12P40; INTERLEUKIN 5; MESSENGER RNA; RIBAVIRIN; VIRUS ANTIGEN; VIRUS RNA;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS CORE;

ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEPACIVIRUS; HEPATITIS C ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; PEPTIDE FRAGMENTS; RIBAVIRIN; RNA, MESSENGER; RNA, VIRAL; T-LYMPHOCYTES; VIRAL CORE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 34247255323     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.11.008     Document Type: Article

References (29)

1. Contreras A.M., Hiasa Y., He W., Terella A., Schmidt E.V., and Chung R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 76 (2002) 8505-8517
2. Cornberg M., Hinrichsen H., Teuber G., Berg T., Naumann U., Falkenberg C., Zeuzem S., and Manns M.P. Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. J. Hepatol. 37 (2002) 843-847
3. Cramp M.E., Rossol S., Chokshi S., Carucci P., Williams R., and Naoumov N.V. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118 (2000) 346-355
4. Crotty S., Maag D., Arnold J.J., Zhong W., Lau J.Y., Hong Z., Andino R., and Cameron C.E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6 (2000) 1375-1379
5. Crotty S., Cameron C., and Andino R. Ribavirin's antiviral mechanism of action: lethal mutagenesis?. J. Mol. Med. 80 (2002) 86-95
6. Di Bisceglie A.M., Conjeevaram H.S., Fried M.W., Sallie R., Park Y., Yurdaydin C., Swain M., Kleiner D.E., Mahaney K., and Hoofnagle J.H. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 123 (1995) 897-903
7. Dusheiko G., Main J., Thomas H., Reichard O., Lee C., Dhillon A., Rassam S., Fryden A., Reesink H., Bassendine M., Norkrans G., Cuypers T., Lelie N., Telfer P., Watson J., Weegink C., Sillikens P., and Weiland O. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J. Hepatol. 25 (1996) 591-598
8. Fang S.H., Hwang L.H., Chen D.S., and Chiang B.L. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J. Hepatol. 33 (2000) 791-798
9. Firpi R.J., Nelson D.R., and Davis G.L. Lack of antiviral effect of a short course of mycophenolate mofetil in patients with chronic hepatitis C virus infection. Liver Transplant. 9 (2003) 57-61
10. Gerlach J.T., Diepolder H.M., Jung M.C., Gruener N.H., Schraut W.W., Zachoval R., Hoffmann R., Schirren C.A., Santantonio T., and Pape G.R. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 117 (1999) 933-941
11. Hultgren C., Milich D.R., Weiland O., and Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. 79 (1998) 2381-2391
12. Ilyin G.P., Langouet S., Rissel M., Delcros J.G., Guillouzo A., and Guguen-Guillouzo C. Ribavirin inhibits protein synthesis and cell proliferation induced by mitogenic factors in primary human and rat hepatocytes. Hepatology 27 (1998) 1687-1694
13. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., Denk H., Desmet V., Korb G., and MacSween R.N. Histological grading and staging of chronic hepatitis. J. Hepatol. 22 (1995) 696-699
14. Jain A., Kashyap R., Demetris A.J., Eghstesad B., Pokharna R., and Fung J.J. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver. Transplant. 8 (2002) 40-46
15. Lanford R.E., Guerra B., Lee H., Averett D.R., Pfeiffer B., Chavez D., Notvall L., and Bigger C. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J. Virol. 77 (2003) 1092-1104
16. Lau G.K., Suri D., Liang R., Rigopoulou E.I., Thomas M.G., Mullerova I., Nanji A., Yuen S.T., Williams R., and Naoumov N.V. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122 (2002) 614-624
17. Lau J.Y., Tam R.C., Liang T.J., and Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35 (2002) 1002-1009
18. Lechner F., Wong D.K., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., Robbins G., Phillips R., Klenerman P., and Walker B.D. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191 (2000) 1499-1512
19. Lee J.H., von Wagner M., Roth W.K., Teuber G., Sarrazin C., and Zeuzem S. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. J. Hepatol. 29 (1998) 29-35
20. Lertora J.J., Rege A.B., Lacour J.T., Ferencz N., George W.J., VanDyke R.B., Agrawal K.C., and Hyslop Jr. N.E. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 50 (1991) 442-449
21. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., and Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339 (1998) 1485-1492
22. Ning Q., Brown D., Parodo J., Cattral M., Gorczynski R., Cole E., Fung L., Ding J.W., Liu M.F., Rotstein O., Phillips M.J., and Levy G. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J. Immunol. 160 (1998) 3487-3493
23. Peavy D.L., Koff W.C., Hyman D.S., and Knight V. Inhibition of lymphocyte proliferative responses by ribavirin. Infect. Immun. 29 (1980) 583-589
24. Powers C.N., Peavy D.L., and Knight V. Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob. Agents Chemother. 22 (1982) 108-114
25. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trépo C., and Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352 (1998) 1426-1432
26. Querenghi F., Yu Q., Billaud G., Maertens G., Trépo C., and Zoulim F. Evolution of hepatitis C virus genome in chronically infected patients receiving ribavirin monotherapy. J. Viral Hepat. 8 (2001) 120-131
27. Tam R.C., Pai B., Bard J., Lim C., Averett D.R., Phan U.T., and Milovanovic T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J. Hepatol. 30 (1999) 376-382
28. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., and Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 25 (1997) 449-458
29. Vollmer J., Rankin R., Hartmann H., Jurk M., Samulowitz U., Wader T., Janosch A., Schetter C., Arthur M., and Krieg A.M. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob. Agents Chemother. 48 (2004) 2314-2317